tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Uremia D014511 33 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Stomach Ulcer D013276 75 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Hypercalcemia D006934 13 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Pompeo A et al. Cyclosporin A, but not FK506, increases arachidonic acid release and inhibits proliferation of pituitary corticotrope tumor cells. 1999 Life Sci. pmid:10096434
Nogueira JM et al. A comparison of recipient renal outcomes with laparoscopic versus open live donor nephrectomy. 1999 Transplantation pmid:10096529
Shapiro R et al. Posttransplant diabetes in pediatric recipients on tacrolimus. 1999 Transplantation pmid:10096540
Hemenway CS and Heitman J Calcineurin. Structure, function, and inhibition. 1999 Cell Biochem. Biophys. pmid:10099825
Holländer GA et al. Molecular and biological actions of cyclosporin A and FK506 on T cell development and function. 1994 Transfus Sci pmid:10155542
Antoniou EA et al. Immunosuppressive effect of combination schedules of brequinar with leflunomide or tacrolimus on rat cardiac allotransplantation. 1999 Microsurgery pmid:10188834
Yasutsune T et al. Vasorelaxation and inhibition of the voltage-operated Ca2+ channels by FK506 in the porcine coronary artery. 1999 Br. J. Pharmacol. pmid:10188984
Zhang W et al. Failure of calcineurin inhibitors to prevent pressure-overload left ventricular hypertrophy in rats. 1999 Circ. Res. pmid:10189360
Fansa H et al. The effect of the immunosuppressant FK 506 on peripheral nerve regeneration following nerve grafting. 1999 J Hand Surg Br pmid:10190602
Meiser BM et al. Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring. 1999 J. Heart Lung Transplant. pmid:10194038
Azuma N et al. Immunosuppression with FK506 in rat arterial allografts: fate of allogeneic endothelial cells. 1999 J. Vasc. Surg. pmid:10194498
Mollison KW et al. Discovery of ascomycin analogs with potent topical but weak systemic activity for treatment of inflammatory skin diseases. 1998 Curr. Pharm. Des. pmid:10197049
De Lima JJ et al. Effects of FK506 in rat and human resistance arteries. 1999 Kidney Int. pmid:10201018
Sloper CM et al. Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. 1999 Ophthalmology pmid:10201592
Nagasaki Y et al. Reversal of hypopigmentation in phenylketonuria mice by adenovirus-mediated gene transfer. 1999 Pediatr. Res. pmid:10203136
Hortelano S et al. Protective effect of cyclosporin A and FK506 from nitric oxide-dependent apoptosis in activated macrophages. 1999 Br. J. Pharmacol. pmid:10205001
Cetinkale O et al. Modulating the functions of neutrophils and lipid peroxidation by FK506 in a rat model of thermal injury. 1999 Burns pmid:10208383
Lütkes P et al. [Quality of life following transplantation. The impact ofa new immunosuppressive substance]. 1999 Zentralbl Chir pmid:10209841
Jani A et al. Modulation of cell-mediated immunity prolongs adenovirus-mediated transgene expression in sciatic nerve. 1999 Hum. Gene Ther. pmid:10210146
Knoll GA and Bell RC Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials. 1999 BMJ pmid:10213717
Green MD and Michaels MG Tacrolimus: effects and side effects. 1999 Pediatr. Infect. Dis. J. pmid:10223694
Ferrari D et al. P2X7/P2Z purinoreceptor-mediated activation of transcription factor NFAT in microglial cells. 1999 J. Biol. Chem. pmid:10224077
Herr I et al. FK506 prevents stroke-induced generation of ceramide and apoptosis signaling. 1999 Brain Res. pmid:10224298
Charco R et al. Serum cholesterol changes in long-term survivors of liver transplantation: a comparison between cyclosporine and tacrolimus therapy. 1999 Liver Transpl Surg pmid:10226111
Taylor DO et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. 1999 J. Heart Lung Transplant. pmid:10226898
Torocsik HV et al. FK506-induced leukoencephalopathy in children with organ transplants. 1999 Neurology pmid:10227644
Göthel SF and Marahiel MA Peptidyl-prolyl cis-trans isomerases, a superfamily of ubiquitous folding catalysts. 1999 Cell. Mol. Life Sci. pmid:10228556
Uno T et al. Pharmacokinetic advantages of a newly developed tacrolimus oil-in-water-type emulsion via the enteral route. 1999 Lipids pmid:10230718
Johnston A and Holt DW Therapeutic drug monitoring of immunosuppressant drugs. 1999 Br J Clin Pharmacol pmid:10233195
Vente C et al. Erosive mucosal lichen planus: response to topical treatment with tacrolimus. 1999 Br. J. Dermatol. pmid:10233234
Lyon CC et al. Recalcitrant pyoderma gangrenosum treated with systemic tacrolimus. 1999 Br. J. Dermatol. pmid:10233300
Jolles S et al. Combination oral and topical tacrolimus in therapy-resistant pyoderma gangrenosum. 1999 Br. J. Dermatol. pmid:10233301
Mollison KW et al. A macrolactam inhibitor of T helper type 1 and T helper type 2 cytokine biosynthesis for topical treatment of inflammatory skin diseases. 1999 J. Invest. Dermatol. pmid:10233764
Akahane M et al. Osteogenic phenotype expression of allogeneic rat marrow cells in porous hydroxyapatite ceramics. 1999 J. Bone Miner. Res. pmid:10234577
Stratta RJ et al. Evolution in pancreas transplantation techniques: simultaneous kidney-pancreas transplantation using portal-enteric drainage without antilymphocyte induction. 1999 Ann. Surg. pmid:10235529
Remy I and Michnick SW Clonal selection and in vivo quantitation of protein interactions with protein-fragment complementation assays. 1999 Proc. Natl. Acad. Sci. U.S.A. pmid:10318894
Genazzani AA et al. Calcineurin controls inositol 1,4,5-trisphosphate type 1 receptor expression in neurons. 1999 Proc. Natl. Acad. Sci. U.S.A. pmid:10318964
Morioka M et al. Activities of calcineurin and phosphatase 2A in the hippocampus after transient forebrain ischemia. 1999 Brain Res. pmid:10320733
Ferlicot S et al. [Smooth muscle mesentery associated with Epstein-Barr virus (EBV). Report of a case in a child with a liver transplant under FK506 regimen]. 1999 Ann Pathol pmid:10320913
Raofi V et al. A prospective randomized trial comparing the efficacy of tacrolimus versus cyclosporine in black recipients of primary cadaveric renal transplants. 1999 Am. J. Surg. pmid:10326847
Garrity ER et al. Suggested guidelines for the use of tacrolimus in lung-transplant recipients. 1999 J. Heart Lung Transplant. pmid:10328140
Ruzicka T et al. Tacrolimus: the drug for the turn of the millennium? 1999 Arch Dermatol pmid:10328199
Schmidt RH et al. Haemolytic-uraemic syndrome after tacrolimus rescue therapy for cortisone-resistant rejection. 1999 Nephrol. Dial. Transplant. pmid:10328486
Kohyama T et al. A potent immunosuppressant FK506 inhibits IL-8 expression in human eosinophils. 1999 Mol. Cell Biol. Res. Commun. pmid:10329481
Tian J and Karin M Stimulation of Elk1 transcriptional activity by mitogen-activated protein kinases is negatively regulated by protein phosphatase 2B (calcineurin). 1999 J. Biol. Chem. pmid:10329725
Nakamura H et al. Induction of autologous graft-versus-host disease after autologous peripheral blood stem cell transplantation. 1999 J. Allergy Clin. Immunol. pmid:10329849
Dresske B et al. Synergistic impact of "WOFIE" on the immunosuppressive potency of FK 506 in a heterotopic heart transplantation model in the rat. 1999 Transplant. Proc. pmid:10331001
Okamoto H The CD38-cyclic ADP-ribose signaling system in insulin secretion. 1999 Mol. Cell. Biochem. pmid:10331647
Iwamoto H et al. Inhibitory effects of FK506 on the development of experimental allergic/immune-mediated blepharoconjunctivitis in Lewis rats by systemic but not by topical administration. 1999 Graefes Arch. Clin. Exp. Ophthalmol. pmid:10333108
Henley SA et al. Lipids increase after solitary pancreas transplantation. 1999 Diabetes Care pmid:10333952
van den Berg JW et al. New immunosuppressive drugs and lung transplantation: last or least? 1999 Thorax pmid:10335012
Shirbacheh MV et al. Pharmacokinetics of intra-arterial delivery of tacrolimus to vascularly isolated rabbit forelimb. 1999 J. Pharmacol. Exp. Ther. pmid:10336506
Gold BG et al. Immunophilin FK506-binding protein 52 (not FK506-binding protein 12) mediates the neurotrophic action of FK506. 1999 J. Pharmacol. Exp. Ther. pmid:10336507
Steg RE et al. Cortical blindness and seizures in a patient receiving FK506 after bone marrow transplantation. 1999 Bone Marrow Transplant. pmid:10338054
Ferrand-Drake M et al. Mitochondrial permeability transition induced DNA-fragmentation in the rat hippocampus following hypoglycemia. 1999 Neuroscience pmid:10338300
Conboy IM et al. Calcineurin and vacuolar-type H+-ATPase modulate macrophage effector functions. 1999 Proc. Natl. Acad. Sci. U.S.A. pmid:10339586
Ma D and Carlow CK Molecular characterization of FKBP13 from filarial parasites. 1999 Mol. Biochem. Parasitol. pmid:10340490
Ruddy SB et al. Design and characterization of a surfactant-enriched tablet formulation for oral delivery of a poorly water-soluble immunosuppressive agent. 1999 Int J Pharm pmid:10341307
Uchio E et al. Soluble intercellular adhesion molecule-1 (ICAM-1), CD4, CD8 and interleukin-2 receptor in patients with Behçet's disease and Vogt-Koyanagi-Harada's disease. 1999 Mar-Apr Clin. Exp. Rheumatol. pmid:10342043
Moffatt SD et al. Potential for improved therapeutic index of FK506 in liposomal formulation demonstrated in a mouse cardiac allograft model. 1999 Transplantation pmid:10342309
Khanna A et al. Impact of Flt-3 ligand on donor-derived antigen presenting cells and alloimmune reactivity in heart graft recipients given adjuvant donor bone marrow. 1998 Transpl. Immunol. pmid:10342736
Dresske B et al. WOFIE augments the immunosuppressive potency of FK-506. Window of opportunity for immunological engagement. 1998 Transpl. Immunol. pmid:10342738
Tacrolimus in the prevention of graft rejection: new indication. Helpful alternative to ciclosporin. 1998 Prescrire Int pmid:10342948
Boehringer M et al. Kaposi's sarcoma after renal transplantation: treatment with liposomal doxorubicin. 1999 Nephrol. Dial. Transplant. pmid:10344407
Siemann G et al. Inhibition of cyclic AMP response element-binding protein/cyclic AMP response element-mediated transcription by the immunosuppressive drugs cyclosporin A and FK506 depends on the promoter context. 1999 Mol. Pharmacol. pmid:10347253
Oddis CV et al. Tacrolimus in refractory polymyositis with interstitial lung disease. 1999 Lancet pmid:10347992
Araki T et al. Increases in [3H]FK-506 and [3H]L-N(G)-nitro-arginine binding in the rat brain after nigrostriatal dopaminergic denervation. 1999 Metab Brain Dis pmid:10348311
Möller A et al. The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. 1999 Drug Metab. Dispos. pmid:10348790
Murata M et al. A new preconditioning regimen with melphalan, busulphan and total body irradiation followed by low-dose immunosuppressant in allogeneic haemopoietic stem cell transplantation. 1999 Br. J. Haematol. pmid:10354150
Zarifian A et al. Cyclosporine-associated thrombotic microangiopathy in renal allografts. 1999 Kidney Int. pmid:10354295
Yang J et al. Sjögren's syndrome in mice carrying the Ipr(cg) gene and the therapeutic efficacy of an immunosuppressive agent FK506. 1999 Pathol. Int. pmid:10355966
Toung TJ et al. Neuroprotective FK506 does not alter in vivo nitric oxide production during ischemia and early reperfusion in rats. 1999 Stroke pmid:10356112
Muramatsu K et al. Limb allotransplantation in rats: combined immunosuppression by FK-506 and 15-deoxyspergualin. 1999 J Hand Surg Am pmid:10357540
Cheng HH et al. Oligomerization state influences the degradation rate of 3-hydroxy-3-methylglutaryl-CoA reductase. 1999 J. Biol. Chem. pmid:10358074
Cao S et al. Long-term outcomes in pediatric liver recipients: comparison between cyclosporin A and tacrolimus. 1999 Pediatr Transplant pmid:10359027
Doolabh VB and Mackinnon SE FK506 accelerates functional recovery following nerve grafting in a rat model. 1999 Plast. Reconstr. Surg. pmid:10359255
Johnson KL and Lawen A Rapamycin inhibits didemnin B-induced apoptosis in human HL-60 cells: evidence for the possible involvement of FK506-binding protein 25. 1999 Immunol. Cell Biol. pmid:10361256
Gummert JF et al. Newer immunosuppressive drugs: a review. 1999 J. Am. Soc. Nephrol. pmid:10361877
Kanoh S et al. Effect of FK506 on ATP-induced intracellular calcium oscillations in cow tracheal epithelium. 1999 Am. J. Physiol. pmid:10362712
Jiang H et al. Tacrolimus versus cyclosporin A: a comparative study on rat renal allograft survival. 1999 Transpl. Int. pmid:10363590
Venz S et al. Contribution of color and power Doppler sonography to the differential diagnosis of acute and chronic rejection, and tacrolimus nephrotoxicity in renal allografts. 1999 Transpl. Int. pmid:10363595
Onsager DR et al. Efficacy of tacrolimus in the treatment of refractory rejection in heart and lung transplant recipients. 1999 J. Heart Lung Transplant. pmid:10363689
Ito F et al. FK506 and cyclosporin A inhibit stem cell factor-dependent cell proliferation/survival, while inducing upregulation of c-kit expression in cells of the mast cell line MC/9. 1999 Arch. Dermatol. Res. pmid:10367710
Przepiorka D et al. Relationship of tacrolimus whole blood levels to efficacy and safety outcomes after unrelated donor marrow transplantation. 1999 Biol. Blood Marrow Transplant. pmid:10371361
Matzinger P Graft tolerance: a duel of two signals. 1999 Nat. Med. pmid:10371494
Kirk AD et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. 1999 Nat. Med. pmid:10371508
Lieberman DN and Mody I Properties of single NMDA receptor channels in human dentate gyrus granule cells. 1999 J. Physiol. (Lond.) pmid:10373689
Cox KL et al. Paediatric liver transplantation: indications, timing and medical complications. 1999 J. Gastroenterol. Hepatol. pmid:10382641
Higgins RM et al. Conversion between cyclosporin and tacrolimus--30-fold dose prediction. 1999 Nephrol. Dial. Transplant. pmid:10383044
Henry ML Cyclosporine and tacrolimus (FK506): a comparison of efficacy and safety profiles. 1999 Clin Transplant pmid:10383101
Koski GK et al. Calcium mobilization in human myeloid cells results in acquisition of individual dendritic cell-like characteristics through discrete signaling pathways. 1999 J. Immunol. pmid:10384103
Leung W et al. Long-term complete remission and immune tolerance after intensive chemotherapy for lymphoproliferative disorders complicating liver transplant. 1999 Transplantation pmid:10385092
Squadrito F et al. Tacrolimus suppresses tumour necrosis factor-alpha and protects against splanchnic artery occlusion shock. 1999 Br. J. Pharmacol. pmid:10385251
Gerhardt U et al. Blood pressure control in kidney transplant recipients: influence of immunosuppression. 1999 J Auton Pharmacol pmid:10385269
Liang H et al. Regulation of angiotensin II-induced phosphorylation of STAT3 in vascular smooth muscle cells. 1999 J. Biol. Chem. pmid:10391929
Hasselder AS The nursing management of a patient receiving Prograf as a primary immunosuppressive agent. 1998 Apr-Jun EDTNA ERCA J pmid:10392057
Horowitz MM et al. Tacrolimus vs. cyclosporine immunosuppression: results in advanced-stage disease compared with historical controls treated exclusively with cyclosporine. 1999 Biol. Blood Marrow Transplant. pmid:10392964
Kochi S et al. Effect of cyclosporin A or tacrolimus on the function of blood-brain barrier cells. 1999 Eur. J. Pharmacol. pmid:10395024
Magee CC et al. Immunosuppressive agents in organ transplantation. 1999 Hosp Med pmid:10396414
Gold BG et al. Efficacy of delayed or discontinuous FK506 administrations on nerve regeneration in the rat sciatic nerve crush model: lack of evidence for a conditioning lesion-like effect. 1999 Neurosci. Lett. pmid:10400242